Home World News FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast...

FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer

June 17, 2026

278

FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki